StockData
Repligen Corp logo

Repligen Corp (RGEN) stock

RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30132% above fair value
$162.18−0.60 (-0.37%)

Close on Nov 17, 2026Market cap $10.37BP/E –Yield –

Repligen total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

No total debt figures for Repligen

Repligen has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Repligen figures

See a number that looks wrong?